Indeed, MTHFD2 downregulation sensitizes breast, liver and kidney cancer cells to the treatment with the chemotherapeutic agent methotrexate15,27,32, and increases the sensitivity of radiation-resistant head and neck squamous cell carcinoma cells to the combinatorial treatment with the radiation sensitizer β-lapachone and radiotherapy47. The gene discussed is MTHFD2; the disease is kidney cancer.